These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


177 related items for PubMed ID: 11258173

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The safety and efficacy of short course (5-day) moxifloxacin vs. azithromycin in the treatment of patients with acute exacerbation of chronic bronchitis.
    DeAbate CA, Mathew CP, Warner JH, Heyd A, Church D.
    Respir Med; 2000 Nov; 94(11):1029-37. PubMed ID: 11127487
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Comparison of the efficacy and safety of moxifloxacin and trovafloxacin for the treatment of acute, bacterial maxillary sinusitis in adults.
    Klossek JM, Siegert R, Nikolaidis P, Arvis P, Leberre MA, Sinusitis Study Group.
    J Laryngol Otol; 2003 Jan; 117(1):43-51. PubMed ID: 12590855
    [Abstract] [Full Text] [Related]

  • 10. A comparison of the safety and efficacy of moxifloxacin (BAY 12-8039) and cefuroxime axetil in the treatment of acute bacterial sinusitis in adults. The Sinusitis Study Group.
    Siegert R, Gehanno P, Nikolaidis P, Bagger-Sjöbäck D, Ibanez JM, Hampel B, Sommerauer B.
    Respir Med; 2000 Apr; 94(4):337-44. PubMed ID: 10845431
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of ten day moxifloxacin 400 mg once daily in the treatment of patients with community-acquired pneumonia. Community Acquired Pneumonia Study Group.
    Patel T, Pearl J, Williams J, Haverstock D, Church D.
    Respir Med; 2000 Feb; 94(2):97-105. PubMed ID: 10714413
    [Abstract] [Full Text] [Related]

  • 12. A multinational, multicentre, non-blinded, randomized study of moxifloxacin oral tablets compared with co-amoxiclav oral tablets in the treatment of acute exacerbation of chronic bronchitis.
    Schaberg T, Ballin I, Huchon G, Bassaris H, Hampel B, Reimnitz P, AECB Study Group.
    J Int Med Res; 2001 Feb; 29(4):314-28. PubMed ID: 11675905
    [Abstract] [Full Text] [Related]

  • 13. A critical review of the fluoroquinolones: focus on respiratory infections.
    Zhanel GG, Ennis K, Vercaigne L, Walkty A, Gin AS, Embil J, Smith H, Hoban DJ.
    Drugs; 2002 Feb; 62(1):13-59. PubMed ID: 11790155
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Moxifloxacin in respiratory tract infections.
    Miravitlles M.
    Expert Opin Pharmacother; 2005 Feb; 6(2):283-93. PubMed ID: 15757424
    [Abstract] [Full Text] [Related]

  • 16. A pharmacoeconomic review of the management of respiratory tract infections with moxifloxacin.
    Simoens S, Decramer M.
    Expert Opin Pharmacother; 2008 Jul; 9(10):1735-44. PubMed ID: 18570606
    [Abstract] [Full Text] [Related]

  • 17. Short-course moxifloxacin therapy for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group.
    Chodosh S, DeAbate CA, Haverstock D, Aneiro L, Church D.
    Respir Med; 2000 Jan; 94(1):18-27. PubMed ID: 10714475
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Moxifloxacin: a respiratory fluoroquinolone.
    Miravitlles M, Anzueto A.
    Expert Opin Pharmacother; 2008 Jul; 9(10):1755-72. PubMed ID: 18570608
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 9.